SOURCE: Century Capital Markets

June 25, 2013 09:30 ET

Global Hemostasis Market Growing Near 10% as Arch Therapeutics Unveils AC5™

NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Century Capital Markets

NEW YORK, NY--(Marketwired - Jun 25, 2013) - The following is an investment opinion on Dendreon Corp (NASDAQ: DNDN), Sequenom (NASDAQ: SQNM), Arch Therapeutics (OTCQB: ARTH) and ISIS Pharmaceuticals (NASDAQ: ISIS). Rapid hemostasis is an urgent requirement in management of trauma and surgical wounds. While hemostasis is just one step in the process of wound healing, it represents an opportunity in medical technology due to the high clinical value of time to cessation of bleeding and the number and types of ways hemostasis can be produced.

Given the opportunity and the relative low barrier to market entry, there are many active companies involved in developing products for the hemostasis market that is currently growing at a 10% rate globally. Such opportunity is responsible for the U.S. representing 32% of the global market. A few of the leaders in the market include companies Dendreon Corp (NASDAQ: DNDN), Sequenom (NASDAQ: SQNM) and ISIS Pharmaceuticals (NASDAQ: ISIS).

Arch Therapeutics (OTCQB: ARTH), seeing that the hemostasis market is in search of a product that works better, faster and more reliably, has developed AC5™, a synthetic peptide comprised of naturally occurring amino acids that when sprayed onto a wound intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. AC5™ provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or clotting ability. Healing occurs normally and naturally. For more information about Arch Therapeutics and the development of its flagship product AC5™ visit

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Century Capital Markets one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. No representation, expressed or implied, is made as to the accuracy, completeness or correctness. We accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information